{"slug":"pt-141-muscle-loss","verification":{"valid":true,"entries":2,"head":"75943762788232ffe290b32a2bb2821b37bc1a630054b36bf43f8e6604b1dd74"},"energy":{"passes":2,"tokens_in":14261,"tokens_out":2315,"tokens_total":16576,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"75943762788232ffe290b32a2bb2821b37bc1a630054b36bf43f8e6604b1dd74"},"provenance":[{"ts":"2026-06-30T01:13:58.879Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Muscle Loss\nSlug: pt-141-muscle-loss\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down\",\"Why PT-141 might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from p","response":"{\n  \"slug\": \"pt-141-muscle-loss\",\n  \"title\": \"PT-141 for Muscle Loss: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nMuscle loss, or sarcopenia in clinical terms, involves progressive decline in muscle mass, strength, and function. This happens when protein breakdown outpaces repair in muscle tissue. Layers include reduced anabolic signaling, inflammation, hormonal shifts, inactivity, and neural drive changes. Over time, fewer motor units fire effectively and satellite cells repair less efficiently. The result is frailty and reduced physical capacity. No direct peptide catalog entry replaces addressing these layers through established means.\\n\\n## Why PT-141 might help you\\n\\nPT-141 acts primarily on melanocortin receptors in the central nervous system to influence arousal pathways. The peptide chain focuses on the sexual / CNS arousal layer.\\n\\n1. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nIf reduced sexual activity or CNS drive contributes to lower overall movement and muscle maintenance, some discuss PT-141 in that context. This remains indirect. No data show direct effects on muscle protein synthesis or satellite cell activity. Any potential link would sit at the speculative tier for muscle loss specifically.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\\n\\nThis section maps layers without repetition. PT-141 addresses one narrow pathway. Other compounds would address separate degeneration layers if present.\\n\\n## What the evidence actually shows\\n\\nHuman trials of PT-141 (bremelanotide) center on hypoactive sexual desire disorder and erectile dysfunction. Phase 3 RECONNECT trials (two identical randomized, double-blind, placebo-controlled studies) enrolled premenopausal women and showed st","tokens_in":14261,"tokens_out":2315,"cost":0,"prev":"genesis","hash":"47d5330dbcaa1a7c7f9812c2e2f8359c0c714233d5d24293d963dbee8f261ccd"},{"ts":"2026-07-17T02:41:07.807Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-muscle-loss","response":"26 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"47d5330dbcaa1a7c7f9812c2e2f8359c0c714233d5d24293d963dbee8f261ccd","hash":"75943762788232ffe290b32a2bb2821b37bc1a630054b36bf43f8e6604b1dd74"}]}